AVI: $30M Public Offering; DMD Drug Heads to Phase II
By Jennifer Boggs
Monday, April 4, 2011
AVI BioPharma Inc., which recently vowed to speed up work on Duchenne's muscular dystrophy (DMD) candidate AVI-4658, is padding its coffers with a $30 million public offering.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.